FDA approval process questioned as it approves new early-stage $56K US/year treatment for Alzheimer’s despite its own panel founding insufficient evidence of efficacy. Only when company changed the study endpoint did it show efficacy compared to placebo.

Medical Mythbusting Commentary for June 8, 2021

In controversial decision, FDA approves first new Alzheimer’s disease drug in nearly 20 years